[Courtesy of ToolGen]
SEOUL -- ToolGen, a South Korean developer of genome editing technology, tied up with T&R Biofab, a 3D bioprinting company, to cooperate in applying induced pluripotent stem cells to gene correction. ToolGen has original technology related to third-generation gene scissors to cut out genetic information in cells.
Induced pluripotent stem cells (iPSCs) are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. iPSCs can be derived directly from adult tissues and bypass the need for embryos.
ToolGen signed a memorandum of understanding with T&R Biofab, which prints human organs and tissues for clinical transplantation, to develop and utilize cells that combine iPSCs and gene calibration technologies. "Inductive pluripotent stem cells are an ideal platform for developing gene correction therapy because they can be segmented into various cells," said ToolGen co-CEO Kim Young-ho.
ToolGen has partnered with VivaZome Therapeutics, an Australian biotech company, to develop therapies based on exosomes which are recognized for their critical role in cell-to-cell communication and transportation. The market for exosome therapeutics has been growing rapidly, and many life science companies have launched tools and systems to support exosome research.
Copyright ⓒ Aju Press All rights reserved.